Advances in the care of patients with intracerebral hemorrhage

Kristine M. Thompson, Sharon Y. Gerlach, H. Keels S Jorn, Jan M. Larson, Thomas G Brott, Julia A. Files

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Intracerebral hemorrhage (ICH), which comprises 15% to 30% of all strokes, has an estimated incidence of 37,000 cases per year. One third of patients are actively bleeding when they present to the emergency department, and hematoma growth during the first hours after ICH onset is thought to be a prime determinant of clinical deterioration. Inflammation, as opposed to ischemia, also negatively affects patient condition. Recombinant activated factor VII is emerging as a potential first-line therapy, especially in warfarin-associated hemorrhage. Corticosteroid therapy is not supported by contemporary studies or by current management guidelines. Aggressive blood pressure reduction is under investigation. Surgical intervention has shown no statistically significant benefit over medical management for patients with ICH in general, although subgroup analysis in a large randomized trial suggested potential benefits from surgery for patients with lobar ICH. Not long ago, ICH was considered virtually untreatable. Diligent efforts in both bench and clinical research are generating hope for patients who experience this catastrophic event.

Original languageEnglish (US)
Pages (from-to)987-990
Number of pages4
JournalMayo Clinic Proceedings
Volume82
Issue number8
DOIs
StatePublished - 2007

Fingerprint

Cerebral Hemorrhage
Patient Care
Hemorrhage
Factor VIIa
Warfarin
Hematoma
Hospital Emergency Service
Adrenal Cortex Hormones
Ischemia
Stroke
Guidelines
Blood Pressure
Inflammation
Incidence
Therapeutics
Growth
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thompson, K. M., Gerlach, S. Y., Jorn, H. K. S., Larson, J. M., Brott, T. G., & Files, J. A. (2007). Advances in the care of patients with intracerebral hemorrhage. Mayo Clinic Proceedings, 82(8), 987-990. https://doi.org/10.4065/82.8.987

Advances in the care of patients with intracerebral hemorrhage. / Thompson, Kristine M.; Gerlach, Sharon Y.; Jorn, H. Keels S; Larson, Jan M.; Brott, Thomas G; Files, Julia A.

In: Mayo Clinic Proceedings, Vol. 82, No. 8, 2007, p. 987-990.

Research output: Contribution to journalArticle

Thompson, KM, Gerlach, SY, Jorn, HKS, Larson, JM, Brott, TG & Files, JA 2007, 'Advances in the care of patients with intracerebral hemorrhage', Mayo Clinic Proceedings, vol. 82, no. 8, pp. 987-990. https://doi.org/10.4065/82.8.987
Thompson, Kristine M. ; Gerlach, Sharon Y. ; Jorn, H. Keels S ; Larson, Jan M. ; Brott, Thomas G ; Files, Julia A. / Advances in the care of patients with intracerebral hemorrhage. In: Mayo Clinic Proceedings. 2007 ; Vol. 82, No. 8. pp. 987-990.
@article{cc070901c72c42439951993f3423a0c9,
title = "Advances in the care of patients with intracerebral hemorrhage",
abstract = "Intracerebral hemorrhage (ICH), which comprises 15{\%} to 30{\%} of all strokes, has an estimated incidence of 37,000 cases per year. One third of patients are actively bleeding when they present to the emergency department, and hematoma growth during the first hours after ICH onset is thought to be a prime determinant of clinical deterioration. Inflammation, as opposed to ischemia, also negatively affects patient condition. Recombinant activated factor VII is emerging as a potential first-line therapy, especially in warfarin-associated hemorrhage. Corticosteroid therapy is not supported by contemporary studies or by current management guidelines. Aggressive blood pressure reduction is under investigation. Surgical intervention has shown no statistically significant benefit over medical management for patients with ICH in general, although subgroup analysis in a large randomized trial suggested potential benefits from surgery for patients with lobar ICH. Not long ago, ICH was considered virtually untreatable. Diligent efforts in both bench and clinical research are generating hope for patients who experience this catastrophic event.",
author = "Thompson, {Kristine M.} and Gerlach, {Sharon Y.} and Jorn, {H. Keels S} and Larson, {Jan M.} and Brott, {Thomas G} and Files, {Julia A.}",
year = "2007",
doi = "10.4065/82.8.987",
language = "English (US)",
volume = "82",
pages = "987--990",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Advances in the care of patients with intracerebral hemorrhage

AU - Thompson, Kristine M.

AU - Gerlach, Sharon Y.

AU - Jorn, H. Keels S

AU - Larson, Jan M.

AU - Brott, Thomas G

AU - Files, Julia A.

PY - 2007

Y1 - 2007

N2 - Intracerebral hemorrhage (ICH), which comprises 15% to 30% of all strokes, has an estimated incidence of 37,000 cases per year. One third of patients are actively bleeding when they present to the emergency department, and hematoma growth during the first hours after ICH onset is thought to be a prime determinant of clinical deterioration. Inflammation, as opposed to ischemia, also negatively affects patient condition. Recombinant activated factor VII is emerging as a potential first-line therapy, especially in warfarin-associated hemorrhage. Corticosteroid therapy is not supported by contemporary studies or by current management guidelines. Aggressive blood pressure reduction is under investigation. Surgical intervention has shown no statistically significant benefit over medical management for patients with ICH in general, although subgroup analysis in a large randomized trial suggested potential benefits from surgery for patients with lobar ICH. Not long ago, ICH was considered virtually untreatable. Diligent efforts in both bench and clinical research are generating hope for patients who experience this catastrophic event.

AB - Intracerebral hemorrhage (ICH), which comprises 15% to 30% of all strokes, has an estimated incidence of 37,000 cases per year. One third of patients are actively bleeding when they present to the emergency department, and hematoma growth during the first hours after ICH onset is thought to be a prime determinant of clinical deterioration. Inflammation, as opposed to ischemia, also negatively affects patient condition. Recombinant activated factor VII is emerging as a potential first-line therapy, especially in warfarin-associated hemorrhage. Corticosteroid therapy is not supported by contemporary studies or by current management guidelines. Aggressive blood pressure reduction is under investigation. Surgical intervention has shown no statistically significant benefit over medical management for patients with ICH in general, although subgroup analysis in a large randomized trial suggested potential benefits from surgery for patients with lobar ICH. Not long ago, ICH was considered virtually untreatable. Diligent efforts in both bench and clinical research are generating hope for patients who experience this catastrophic event.

UR - http://www.scopus.com/inward/record.url?scp=34547641051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547641051&partnerID=8YFLogxK

U2 - 10.4065/82.8.987

DO - 10.4065/82.8.987

M3 - Article

C2 - 17673068

AN - SCOPUS:34547641051

VL - 82

SP - 987

EP - 990

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -